UniPharma Co., Ltd. (TPEX:6621)
Taiwan · Delayed Price · Currency is TWD 11.45
0.00 (0.00%)
Sep 8, 2026, 12:51 PM CST
UniPharma Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 83.87 | 88.44 | 93.46 | 103.22 | 128.11 | 105.39 |
Revenue Growth | -5.17% | -5.36% | -9.46% | -19.43% | 21.56% | -23.98% |
Gross Profit Gross Profit Growth | 42.65 | 47.22 | 48.71 | 51.02 | 74.62 | 59.33 |
Operating Income Operating Income Growth | -45.79 | -44.13 | -30.82 | -27.31 | -20.88 | -40.22 |
Net Income Net Income Growth | -40.1 | -40.54 | -24.82 | -21.81 | -6.45 | -74.41 |
Earnings Per Share EPS Growth | -1.13 | -1.14 | -0.70 | -0.61 | -0.18 | -2.11 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Medical Equipment Medical Equipment Growth | 44.02 | 54.03 | 63.42 | 71.2 | 92.46 | 67.25 |
Drugs Drugs Growth | 16.72 | 13.92 | 13.86 | 15.03 | 15.36 | 14.4 |
Diagnostic Reagent Diagnostic Reagent Growth | 8.08 | 7.65 | 7.48 | 15.07 | 19.48 | 22.87 |
Medical Testing Medical Testing Growth | 5.93 | 5.86 | 6.85 | - | - | - |
Other Other Growth | 9.13 | 7 | 1.85 | 1.93 | 0.81 | - |
Total Total Growth | 83.87 | 88.44 | 93.46 | 103.22 | 128.11 | 105.39 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 107.59 | 135.36 | 157.18 | 167.14 | 162.26 | 175.46 |
Total Debt Total Debt Growth | 12.32 | 10.96 | 14.78 | 0.27 | 3.53 | 6.99 |
Net Cash (Debt) Net Cash Growth | 95.27 | 124.39 | 142.4 | 166.87 | 158.73 | 168.46 |
Net Cash Growth | -23.41% | -12.64% | -14.67% | 5.13% | -5.78% | -1.63% |
Net Cash Per Share Net Cash Per Share Growth | 2.68 | 3.50 | 4.01 | 4.70 | 4.47 | 4.79 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -33.83 | -36.67 | -14.32 | 12.03 | -31.65 | -12.93 |
Capital Expenditures CapEx Growth | -1.16 | -1.31 | -0.79 | -8.11 | -0.44 | -0.61 |
Free Cash Flow Free Cash Flow Growth | -34.99 | -37.98 | -15.11 | 3.92 | -32.09 | -13.54 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 50.86% | 53.39% | 52.12% | 49.42% | 58.25% | 56.29% |
Operating Margin | -54.60% | -49.89% | -32.98% | -26.45% | -16.30% | -38.16% |
Pretax Margin | -47.80% | -45.84% | -26.56% | -21.13% | -5.49% | -70.60% |
Profit Margin | -47.80% | -45.84% | -26.56% | -21.13% | -5.03% | -70.60% |
FCF Margin | -41.71% | -42.94% | -16.17% | 3.80% | -25.05% | -12.85% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 23.14 | 23.14 | 23.14 | 23.14 | 23.14 |
P/FCF Ratio | - | - | - | 133.90 | - | - |
PS Ratio | 4.85 | 4.88 | 5.26 | 5.09 | 4.30 | 3.79 |